Phase III trial of bevacizumab biosimilar (ONS-1045) in patients with cancer

Trial Profile

Phase III trial of bevacizumab biosimilar (ONS-1045) in patients with cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncobiologics
  • Most Recent Events

    • 20 Apr 2015 New trial record
    • 15 Apr 2015 This trial, the first in a global phase III programme, is expected to be initiated in the fourth quarter of 2015, after pharmacokinetic data from a pivotal pharmacokinetic study have been reported, according to an Oncobiologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top